Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 40%GRADE not reported 0 · 0%Very low 2 · 40%Low 1 · 20%Moderate 0 · 0%High 0 · 0%

IVIg vs placebo

All‐cause mortality · NSTI

Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 1.17 [0.42, 3.23]
1 study · 100 participants
Low

IVIg vs corticosteroids

Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs no IVIG

Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

It is very uncertain whether intravenous immunoglobulin (IVIG) changes SJS/TEN‐specific mortality (time to compared with no IVIG (very low certainty).

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
RR 0.33 [0.04, 2.91]
1 study · 36 participants
Very low

Cyclosporin vs intravenous immunoglobulin (IVIG)

Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

It is very uncertain whether cyclosporin changes disease‐specific mortality (time to compared with intravenous immunoglobulin (IVIG) (very low certainty).

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
RR 0.13 [0.02, 0.98]
1 study · 22 participants
Very low

Etanercept vs intravenous immunoglobulin (IVIG)

Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found